According to FutureWise analysis the market for Parkinson’s Disease Drugs in 2023 is US$ 6.46 billion, and is expected to reach US$ 10.62 billion by 2031 at a CAGR of 6.40%.
Parkinson's disease is a movement-control condition that affects the neurological system. When nerve cells (neurons) in the substantia nigra (SN) region of the brain become injured or die, Parkinson's disease occurs. The problem usually starts slowly and gets worse over time. Parkinson's disease is characterised by tremors, muscular rigidity, trouble walking, maintaining body balance, and coordination, to name a few symptoms. Speaking and sleeping difficulties, thinking and memory problems, and behavioural abnormalities may develop as the illness advances. Parkinson's disease is more common in males than in women, according to the Parkinson's Foundation. Men had a higher incidence than women, with a risk of 1.5 times that of women. It is most commonly found in those over 60 years old. Some of the symptoms of Parkinson's disease can be relieved by medications as well as alternative therapies such as exercise. Medications including levodopa, safinamide, pramipexole, benztropine, and selegiline are important therapy options for Parkinson's disease patients. The market is being driven by two major factors: an ageing population and an increase in the prevalence of neurological illnesses. Furthermore, rising R D spending and the number of medications in the pipeline are projected to propel the industry forward. The high cost of treatment and a lack of expertise for early diagnosis, on the other hand, are expected to limit market expansion.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Parkinson’s Disease Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Parkinson’s Disease Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.